Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Early Improvement and Marriage Are Determinants of the 12-Month Treatment Outcome of Paroxetine in Outpatients with Panic Disorder.

Watanabe T, Ueda M, Ishiguro S, Hayashi Y, Aoki A, Shinozaki M, Kato K, Akiyama K, Shimoda K.

Clin Psychopharmacol Neurosci. 2017 Nov 30;15(4):382-390. doi: 10.9758/cpn.2017.15.4.382.

2.

Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine.

Tokuoka H, Nishihara M, Fujikoshi S, Yoshikawa A, Kuga A.

Neuropsychiatr Dis Treat. 2017 Sep 25;13:2457-2467. doi: 10.2147/NDT.S143093. eCollection 2017.

3.

Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.

Oluboka OJ, Katzman MA, Habert J, McIntosh D, MacQueen GM, Milev RV, McIntyre RS, Blier P.

Int J Neuropsychopharmacol. 2018 Feb 1;21(2):128-144. doi: 10.1093/ijnp/pyx081.

4.

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.

Katzman MA, Nierenberg AA, Wajsbrot DB, Meier E, Prieto R, Pappadopulos E, Mackell J, Boucher M.

J Clin Psychopharmacol. 2017 Oct;37(5):555-561. doi: 10.1097/JCP.0000000000000775.

5.

Is the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?

Çiftçi A, Ulaş H, Topuzoğlu A, Tunca Z.

Noro Psikiyatr Ars. 2016 Sep;53(3):245-252. doi: 10.5152/npa.2015.10141. Epub 2016 Sep 1.

6.

Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.

Yoshida K, Roberts R, Suzuki T, Lebowitz B, Reeves S, Howard R, Abe T, Mimura M, Uchida H.

Am J Geriatr Psychiatry. 2017 Jul;25(7):708-716. doi: 10.1016/j.jagp.2017.01.016. Epub 2017 Jan 30.

PMID:
28215900
7.

Default mode network deactivation during emotion processing predicts early antidepressant response.

Spies M, Kraus C, Geissberger N, Auer B, Klöbl M, Tik M, Stürkat IL, Hahn A, Woletz M, Pfabigan DM, Kasper S, Lamm C, Windischberger C, Lanzenberger R.

Transl Psychiatry. 2017 Jan 24;7(1):e1008. doi: 10.1038/tp.2016.265.

8.

Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials.

Shi L, Wang J, Xu S, Lu Y.

Drug Des Devel Ther. 2016 Nov 25;10:3899-3907. eCollection 2016.

9.

Predicting relapse after antidepressant withdrawal - a systematic review.

Berwian IM, Walter H, Seifritz E, Huys QJ.

Psychol Med. 2017 Feb;47(3):426-437. doi: 10.1017/S0033291716002580. Epub 2016 Oct 27. Review.

10.

Respiratory sinus arrhythmia reactivity to a sad film predicts depression symptom improvement and symptomatic trajectory.

Panaite V, Hindash AC, Bylsma LM, Small BJ, Salomon K, Rottenberg J.

Int J Psychophysiol. 2016 Jan;99:108-13. doi: 10.1016/j.ijpsycho.2015.12.002. Epub 2015 Dec 8.

11.

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation.

Loebel A, Citrome L, Correll CU, Xu J, Cucchiaro J, Kane JM.

BMC Psychiatry. 2015 Oct 31;15:271. doi: 10.1186/s12888-015-0629-0.

12.

Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder.

McIntyre RS, Gorwood P, Thase ME, Liss C, Desai D, Chen J, Bauer M.

J Clin Psychopharmacol. 2015 Dec;35(6):706-10. doi: 10.1097/JCP.0000000000000416.

13.

Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy.

Hellerstein DJ, Flaxer J.

Core Evid. 2015 Apr 20;10:49-62. doi: 10.2147/CE.S54075. eCollection 2015. Review.

14.

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.

Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, Stingl JC, Tsai SJ, Kubo M, Klein TE, Weinshilboum R.

Transl Psychiatry. 2015 Apr 21;5:e553. doi: 10.1038/tp.2015.47. Erratum in: Transl Psychiatry. 2016 Nov 1;6(11):e937.

15.

A Prospective, Longitudinal Study of the Effect of Remission on Cortical Thickness and Hippocampal Volume in Patients with Treatment-Resistant Depression.

Phillips JL, Batten LA, Tremblay P, Aldosary F, Blier P.

Int J Neuropsychopharmacol. 2015 Mar 30;18(8). pii: pyv037. doi: 10.1093/ijnp/pyv037.

16.

Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine.

Furey ML, Drevets WC, Szczepanik J, Khanna A, Nugent A, Zarate CA Jr.

Int J Neuropsychopharmacol. 2015 Mar 28;18(8). pii: pyv028. doi: 10.1093/ijnp/pyv028.

17.

Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.

Kato M, Serretti A, Nonen S, Takekita Y, Wakeno M, Azuma J, Kinoshita T.

Transl Psychiatry. 2015 Feb 24;5:e513. doi: 10.1038/tp.2015.6.

18.

Treatment-resistant depression in primary care across Canada.

Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, Mcintyre RS, Kennedy SH.

Can J Psychiatry. 2014 Jul;59(7):349-57.

19.

Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.

Khan A, Sambunaris A, Edwards J, Ruth A, Robinson DS.

Int Clin Psychopharmacol. 2014 Mar;29(2):86-92. doi: 10.1097/YIC.0000000000000016.

20.

Depression remission after six months of collaborative care management: role of initial severity of depression in outcome.

Angstman KB, Pietruszewski P, Rasmussen NH, Wilkinson JM, Katzelnick DJ.

Ment Health Fam Med. 2012 Jun;9(2):99-106.

Supplemental Content

Support Center